Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

trastuzumab

Drug and asset intelligence for trastuzumab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Stage
Development stage unavailable

Sponsor company

Roche →

Recent signals(2)

ClinicalJune 17, 2026

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.

ClinicalJune 17, 2026

Phase III Trial Compares 6 vs. 12 Months of HER2-Targeted Therapy in Breast Cancer

A phase III trial is investigating whether 6 months of HER2-targeted therapy is more effective than 12 months for HER2-positive breast cancer patients who achieved a pathologic complete response after neoadjuvant chemotherapy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Breast Cancer →
HER2-positive Breast Cancer →

Therapeutic areas

Breast Cancer →
HER2-positive Breast Cancer →
Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.